Sarah E M Herman
Overview
Explore the profile of Sarah E M Herman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
3183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baskar S, Peng H, Gaglione E, Carstens E, Lindorfer M, Ahn I, et al.
Blood
. 2025 Jan;
PMID: 39774793
Monoclonal antibodies (mAbs) improve survival of patients with mature B-cell malignancies. Fcγ-receptor dependent effector mechanisms kill tumor cells but can promote antigen loss through trogocytosis, contributing to treatment failures. Cell-bound...
2.
Zhang D, Harris H, Chen J, Judy J, James G, Kelly A, et al.
Blood
. 2022 Nov;
141(13):1584-1596.
PMID: 36375120
Bruton tyrosine kinase (BTK) is essential for B-cell receptor (BCR) signaling, a driver of chronic lymphocytic leukemia (CLL). Covalent inhibitors bind C481 in the active site of BTK and have...
3.
Sun C, Chen Y, Zurita A, Baptista M, Pittaluga S, Liu D, et al.
Blood Adv
. 2022 Mar;
7(1):145-158.
PMID: 35358998
In chronic lymphocytic leukemia (CLL), B-cell receptor signaling, tumor-microenvironment interactions, and somatic mutations drive disease progression. To better understand the intersection between the microenvironment and molecular events in CLL pathogenesis,...
4.
Soleimani A, Navarro A, Liu D, Herman S, Chuang S, Slavutsky I, et al.
Leuk Lymphoma
. 2021 Nov;
63(4):911-917.
PMID: 34781807
Conventionally, mantle cell lymphoma (MCL) is an aggressive CD5-positive B-cell malignancy with poor prognosis and limited survival. However, a small subset of patients presents with indolent disease and can be...
5.
Desai S, Mo C, Gaglione E, Yuan C, Stetler-Stevenson M, Tian X, et al.
Leuk Lymphoma
. 2021 Mar;
62(8):1816-1827.
PMID: 33653216
High-risk cytogenetics and minimal residual disease (MRD) after chemoimmunotherapy (CIT) predict unfavorable outcome in chronic lymphocytic leukemia (CLL). This phase 2 study investigated risk-adapted CIT in treatment-naïve CLL (NCT01145209). Patients...
6.
Ahn I, Tian X, Ipe D, Cheng M, Albitar M, Tsao L, et al.
J Clin Oncol
. 2020 Oct;
39(6):576-585.
PMID: 33026937
Purpose: Randomized trials established the superiority of ibrutinib-based therapy over chemoimmunotherapy in chronic lymphocytic leukemia. Durability of progression-free survival (PFS) with ibrutinib can vary by patient subgroup. Clinical tools for...
7.
Cohen A, Davis M, Herman S
Mil Med
. 2020 Oct;
186(5-6):123-128.
PMID: 33007073
In early March 2020, Johns Hopkins University Applied Physics Lab hosted an Association of Military Surgeons of the United States regional conference to address medical demands of the future battlefield...
8.
Sun C, Nierman P, Kendall E, Cheung J, Gulrajani M, Herman S, et al.
Blood
. 2020 Mar;
136(1):93-105.
PMID: 32202637
Inhibition of the B-cell receptor pathway, and specifically of Bruton tyrosine kinase (BTK), is a leading therapeutic strategy in B-cell malignancies, including chronic lymphocytic leukemia (CLL). Target occupancy is a...
9.
Alsadhan A, Cheung J, Gulrajani M, Gaglione E, Nierman P, Hamdy A, et al.
Clin Cancer Res
. 2020 Feb;
26(12):2800-2809.
PMID: 32054731
Purpose: To determine the pharmacodynamic relationship between target occupancy of Bruton tyrosine kinase (BTK) and inhibition of downstream signaling. Patients And Methods: Patients with chronic lymphocytic leukemia (CLL) enrolled in...
10.
Yin S, Gambe R, Sun J, Martinez A, Cartun Z, Regis F, et al.
Cancer Cell
. 2019 Feb;
35(2):283-296.e5.
PMID: 30712845
SF3B1 is recurrently mutated in chronic lymphocytic leukemia (CLL), but its role in the pathogenesis of CLL remains elusive. Here, we show that conditional expression of Sf3b1-K700E mutation in mouse...